FAAH Inhibitors
FAAH inhibitors are drugs that block the enzyme that breaks down anandamide — they are not terpenes, despite the topic tag.
Heads up: this topic was filed as a 'terpene' article, but FAAH inhibitors are not terpenes. They are pharmacological compounds — mostly synthetic small molecules — that block fatty acid amide hydrolase, the enzyme that degrades anandamide. We are writing the honest version instead of forcing a terpene template onto a drug class. If you came here looking for a terpene, you probably want linalool, myrcene, or limonene.
Why this isn't a terpene article
Terpenes are volatile hydrocarbons built from isoprene units — monoterpenes (C10) like Myrcene and Limonene, or sesquiterpenes (C15) like Beta-Caryophyllene. FAAH inhibitors are something else entirely: they are synthetic (or, in a few cases, natural product–derived) small molecules designed to bind the active site of an enzyme. They have no characteristic aroma, no boiling point relevant to vaporization in cannabis flower, and they are not produced by Cannabis sativa. Calling FAAH inhibitors a terpene would be a category error, so the standard terpene infobox fields (formula, boiling point, aroma) do not apply. The rest of this article treats the topic correctly, as a drug class that interacts with the endocannabinoid system.
What FAAH does, and what inhibitors do to it
Fatty acid amide hydrolase (FAAH) is a membrane-bound serine hydrolase that breaks down several fatty acid amides, most importantly anandamide (N-arachidonoylethanolamine, AEA) — one of the two principal endocannabinoids, alongside 2-arachidonoylglycerol (2-AG) [1][2]. When FAAH is inhibited, anandamide accumulates in tissues and signals more strongly at CB1 and CB2 receptors Strong evidence. This is mechanistically distinct from THC, which directly agonizes CB1. The theoretical appeal of FAAH inhibitors is that they boost endogenous tone only where and when anandamide is already being released, which in animal models produces analgesia and anxiolysis with less of the intoxication and tolerance seen with direct CB1 agonists [3] Weak / limited.
Representative compounds
- URB597 (KDS-4103): A carbamate-based irreversible FAAH inhibitor widely used as a research tool. Robust effects in rodent anxiety and pain models [3][evidence:strong for preclinical]; never advanced to approval.
- PF-04457845 (Pfizer): A selective, orally bioavailable FAAH inhibitor. A randomized controlled trial in cannabis use disorder reported reductions in withdrawal symptoms and cannabis use over four weeks [4][evidence:weak — single trial, modest sample].
- JNJ-42165279 (Janssen): Tested in social anxiety disorder and major depressive disorder with mixed-to-disappointing results Weak / limited.
- BIA 10-2474 (Bial): Caused one death and severe neurological injury to four other volunteers in a Phase 1 trial in Rennes, France in 2016 [5][6]. Subsequent analysis suggested off-target lipase inhibition, not FAAH inhibition per se, was responsible [7]. The episode does not invalidate the FAAH target, but it ended much of the industry enthusiasm for the class.
Evidence in humans
Despite roughly two decades of development, no FAAH inhibitor is approved for any indication anywhere Strong evidence. Human trials have targeted pain, anxiety, PTSD, depression, and cannabis use disorder. Results have generally been underwhelming relative to preclinical promise — a pattern common to endocannabinoid drug development. The PF-04457845 cannabis withdrawal trial is the most cited positive human result [4]. A separate PF-04457845 trial in osteoarthritis pain failed to beat placebo [8][evidence:strong negative]. The honest summary: FAAH inhibition reliably raises anandamide in humans, but raising anandamide has not yet translated into clear clinical benefit at the doses and durations tested.
Relevance to cannabis users
A few connections are worth flagging:
- CBD and FAAH: Early in vitro work suggested cannabidiol weakly inhibits FAAH in some species, but the effect appears species-specific and is much weaker in human FAAH than in rat FAAH [9] Disputed. The popular claim that 'CBD works by raising anandamide via FAAH inhibition' is overstated.
- Genetic variation: A common human FAAH variant (C385A, rs324420) reduces enzyme activity and is associated with higher circulating anandamide; it has been linked, inconsistently, to differences in anxiety, pain sensitivity, and cannabis use patterns [10] Weak / limited.
- No terpene is a meaningful FAAH inhibitor at physiologically relevant concentrations. Claims that specific terpenes 'boost your high by inhibiting FAAH' are not supported by good human data No data.
Bottom line
FAAH inhibitors are a pharmacologically interesting drug class that targets the endocannabinoid system upstream of the cannabinoid receptors. The biology is real and well characterized; the clinical payoff has so far been small. They are not terpenes, not cannabinoids, and not present in cannabis flower in any meaningful amount.
Sources
- Peer-reviewed Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604):83-87.
- Peer-reviewed McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74:411-432.
- Peer-reviewed Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9(1):76-81.
- Peer-reviewed D'Souza DC, Cortes-Briones J, Creatura G, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35-45.
- Peer-reviewed Kerbrat A, Ferré JC, Fillatre P, et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med. 2016;375(18):1717-1725.
- Reported Butler D. French clinical trial disaster: scientists question pre-clinical tests. Nature News. 2016.
- Peer-reviewed van Esbroeck ACM, Janssen APA, Cognetta AB, et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017;356(6342):1084-1087.
- Peer-reviewed Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153(9):1837-1846.
- Peer-reviewed Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845-852.
- Peer-reviewed Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA. 2002;99(12):8394-8399.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.